Urine collection Samples were collected from all individuals according to a uniform study protocol, following the recommendations on urine proteomic sample collection. 8 The second-or third-morning midstream urine was collected to sterile urine containers 1 to 3 h after previous urination. The pH of each sample was stabilized at 7.2 by addition of 1/10th vol. of 1M HEPES pH 7.2 immediately after collection. Then, samples were vortexed for 2 min, centrifuged at 3000 × g at room temperature for 10 min to clear the debris, filtered (0.4-µm filter, Rotilabo-Spritzenfilter, Roth, Karlsruhe, Germany), and portioned into 1-ml aliquots that were stored at -80°C before further use.
Sample filtration Membrane filters of the 10 kDa cut-off (Amicon Ultra-0.5, UFC501 096, Millipore, Billerica, United States) were washed twice with MilliQ (MQ) water prior to use. Urine was centrifuged through the membrane at 14,000 × g for 15 min. Next, 500 µl MQ was added to the retentate and centrifugation step was repeated. To recover the concentrated and desalted sample, the filter was placed upside down and centrifuged in a clean microcentrifuge tube for 2 min at 1000 × g. The protein concentration was measured by the Bradford method. Aliquots of samples were stored at -80°C.
Sample preparation, study design, and mass spectrometry settings The study design is illustrated in Supplementary material online, FIGURE S1. Sample preparation, pooling, labeling, and MS measurements were performed as described elsewhere.
9 Shortly, 30 IgAN samples were divided into 3 disease pooled samples (DPSs I, II, and III), and similarly, 30 control samples were divided into 3 control pooled samples (CPSs I, II, and III). Age and sex matching was preserved within the 3 pairs of pooled sample groups. All DPSs and CPSs were obtained in 2 technical replicates (marked A and B) each, making a set of 12 pooled samples to be compared after isobaric tags for relative and absolute quantitation (iTRAQ) labeling. As 4-plex iTRAQ was used, 2 technical replications of DPSs and CPSs were compared in 1 isoelectric focusing/liquid chromatography-mass spectrometry/mass spectrometry (IEF/LC-MS/MS) experiment. To analyze 12 samples, we conducted a set of 3 independent IEF/LC-MS/MS experiments. Aliquots with extracted peptides were stored at -80°C for the IEF/LC-MS/MS analysis.
Mass spectrometry: qualitative MS/MS data processing
The MS/MS data were pre-processed with Mascot Distiller (v. 2.3.2.0, Matrix Science, London, United Kingdom). Data search using the MASCOT search engine was conducted on the Swiss-Prot database with the taxonomy restricted to Homo sapiens (20,236 sequences) in a 3-step procedure described elsewhere to calculate MS and MS/MS measurement errors and to recalibrate the data for the repeated MASCOT could be a good indicator of treatment response are still being sought.
It was previously reported that the presence of urinary proteins is indicative of glomerular damage and interstitial fibrosis. Therefore, one of the most promising diagnostic tools is urine proteomics, particularly because the biological material can be obtained easily and comes directly from the diseased organ, the kidney. During the last decade, several valuable studies have linked proteomics to IgAN, and a number of urine proteins considered IgAN-specific have been reported. 4, 5 However, the quality of the final results was limited by differences in the methodology of urine collection, the number of patients and control subjects studied, and their proteinuria and GFR values. Those factors could considerably confound data interpretation in the previous studies.
The aim of our research was to study urine proteomics in patients with IgAN in comparison with age-and sex-matched healthy controls. Considering the challenges in methodology used in other studies, 4,5 we proposed a new protocol for urine collection and preparation. The key aim was to limit the risk of protein degradation. First, all samples were collected from the second-or third-morning midstream urine, 1 to 3 h after previous urination. Second, as the presence of low-molecular-weight (LMW) proteinuria in IgAN indicated a less favorable outcome with higher incidence of chronic renal failure (47%) compared with those patients who did not have LMW proteinuria (10%); therefore, we also searched short peptides (≥2).
6 To the best of our knowledge, this has been the first report of IgAN urine proteomics profiling performed according to this protocol. As a result, we have defined several new proteins that are unique for patients with IgAN.
PATIENTS AND METHODS Groups of patients
The study included 30 patients with IgAN and 30 healthy age-and sex-matched volunteers serving as controls. Demographic and clinical data of both groups are presented in Supplementary material online, TABLE S1. Patients with biopsy-proven IgAN at different stages of chronic kidney disease (CKD) and older than 18 years were included. The inclusion criteria for the control group were as follows: age older than 18 years and absence of any kidney disease or other chronic diseases requiring treatment. The exclusion criteria for both groups included: active infection, history of malignancy, previous organ transplantation, or current pregnancy. To estimate GFR, we used the Chronic Kidney Disease Epidemiology Collaboration equations, which are the most accurate, have been evaluated in large diverse populations, and are applicable for clinical use.
7 The study protocol was approved by the local ethics committee and informed consent was obtained from all participants. The study was performed in accordance with the Declaration of Helsinki.
to remove systematic bias. Protein ratios were calculated as the median ratio of their peptide's ratios. The statistical significance of a single protein ratio was assessed by an in-house program, Diffprot.
12 Calculated P values were adjusted for multiple testing using a false discovery rate-controlling procedure, yielding protein ratio q values.
Protein network analysis
The proteins identified in our study were searched in the STRING database version 9.1 for protein-protein interactions. 13 RESULTS Data on kidney function in both groups are presented in Supplementary material online, TABLE S1. Of 30 patients with IgAN, 15 were treated with angiotensin-converting enzyme inhibitors and 19 with immunosuppression, mainly oral steroids. The number of patients at different stages of CKD were as follows: 10 patients in stage 1, 6 in stage 2, 10 in stage 3, and 4 in stage 4.
A set of 30 IgAN samples was divided into 3 subsets, containing 10 samples each, which were then pooled into 3 DPSs: I, II, and III. Similarly, control set was divided into 3 CPSs: I, II, and III, retaining age and sex matching within the subsets. In addition, 2 technical replicates of each DPS or CPS were prepared, further denoted A or B to assess the intragroup technical variability.
As a result of qualitative analysis (peptide and protein identification) in each of the 3 IEF/LC-MS-MS/MS experiments, 761, 951, and 956 proteins were identified, respectively, each represented by 2 or more peptides (Supplementary material online, TABLE S2). One-peptide hits were not taken into account in subsequent quantitative analysis.
Qualitative results (protein lists) from 3 IEF/LC-MS-MS/MS experiments were combined, resulting in a dataset with all 1238 proteins identified by at least 2 peptides. Within this dataset, identified proteins were again grouped based on identical peptide sets and each group was treated as a single protein cluster in further processing. After quantitative analysis, the final combined protein list accepted for quantitation contained 1176 proteins. However, 627 of these proteins were common for all replicates of the experiment.
The statistical analysis of the quantitative results of the 3 IEF/LC-MS/MS experiments revealed 18 proteins that were differently populated (with P <0.05) in the urine of patients with IgAN as compared with healthy controls. The differential protein list is presented in Supplementary material online, TABLE S3. 14-37 The differences in protein levels (protein ratio) can be substantial; in some cases, the levels may be even 5-fold higher. Among DPSs, 2 were downregulated and 16 were upregulated in patients with IgAN.
All proteins identified in our study were searched in the STRING database, which defines a metric called "confidence score" to describe interaction confidence. We fetched all interactions for our dataset, which had a medium confidence search.
10 The initial search parameters were set as follows: enzyme, semi-trypsin; fixed modification, cysteine modification by MMTS; iTRAQ labeling of lysine side chains and the N-terminus of peptides; variable modifications, oxidation; missed cleavages, 1. For the repeated search, the recalibrated data from all gel sections were merged into 1 input file and searched using MASCOT against the Swiss-Prot database supplemented with the decoy database to obtain the statistical assessment of the identification of each peptide by a joined target/decoy database search strategy. 11 This procedure provided q value estimates for each peptide spectrum match (PSM) in the dataset. All PSMs with q values exceeding 0.01 were removed from further analysis. A protein was regarded as reliably identified if at least 2 peptides originating from this protein were found. Proteins identified by a subset of peptides from another protein were excluded from the analysis. Proteins that exactly matched the same set of peptides were clustered into 1 group/cluster (FIGURE 1). The MS/MS spectra of peptides fulfilling the acceptance criteria were subjected to quantitative analysis to obtain a list of proteins differentially populated between a set of 3 DPSs and 3 CPSs.
iTRAQ quantitative analysis For protein quantitation, only unique peptides (i.e., peptides belonging only to 1 protein/cluster) were included. In the first step, using the MascotDistiller program, iTRAQ reporter ion peaks were detected in the preprocessed MS/MS spectra; next, their intensities were corrected for isotope impurity using the information provided by the reagent manufacturer. For each spectrum, a geometric mean of 2 reporter ion intensities belonging to 1 study group (DPSs or CPSs) was separately calculated. A ratio of these mean values (CPS mean divided by DPS mean) was reported as the peptide ratio. If more than 1 spectrum was obtained for a peptide in a single IEF/LC-MS/MS experiment, the median peptide ratio value from all spectra was used. Prior to the protein ratio calculations, peptide ratios were median-normalized 
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There is evidence that the complement system plays a critical role in the pathogenesis of IgAN. [43] [44] [45] [46] [47] [48] [49] It is known that C3 glomerular deposition is detected in more than 90% of patients with IgAN, which indirectly proves that complement activation is involved in glomerular damage in IgAN. 43 Moreover, dimeric and polymeric IgA have been found to activate the complement system in the glomeruli via alternative or lectin pathways, thus leading to glomerular damage.
44,45 On the other hand, mesangial C3 deposition is an independent risk factor for IgAN progression. 46 In any event, the activation of C3 and C3 convertase production is the key cause of histological damage induced following the formation of the membrane attack complex (C5b-9).
47 Therefore, it would be important for the future studies of urine proteomics in IgAN to distinguish extrafrom intraglomerular C3 component. Also, an increased serum level of complement components for, e.g., factor H, properdin, and regulatory proteins, has been reported in IgAN.
48 The concentrations of activated C3 were elevated in 30% of the patients with IgAN and correlated positively with hematuria.
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One can argue that the administration of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonists, antiplatelet drugs, or score of 0.4 and higher. The resulting interactome had 13 nodes and 34 interactions (FIGURE 2). DISCUSSION The aim of the study was to evaluate urine proteomics of patients with IgAN. For the purpose of this experiment, patients with stable renal function, assessed by the serum creatinine concentration, GFR level, and daily proteinuria excretion, were selected and compared with healthy volunteers. We found specific proteins that were identified only in the IgAN cohort as compared with the control group. What differentiates our study from others is that we investigated also short proteins (≥2 peptides). Sometimes they are estimated to be produced in large amounts by proteolysis of large proteins. Therefore, their examination could be a novel way to establish IgAN biomarkers. The analysis of short peptides in the serum from patients with IgAN were previously reported.
38 For decades, nephrologists have searched for diagnostic methods that would be repetitive, sufficiently sensitive, safe (especially compared with renal biopsy), and that would enable continuous monitoring and stratifying risk for progression of the disease, particularly in the ambulatory care.
39-41 It would seem that nephrologists are in the privileged situation because the primary biological material that we usually assess-the urine-comes almost directly from the affected organ. Therefore, its skilful evaluation should allow us to establish a prompt and accurate diagnosis. Consequently, many people believe that proteomic studies of the urine have great potential to be used both in the diagnosis and evaluation of kidney disease activity, especially of glomerulonephritis.
We found increased urinary concentrations of complement components, coagulation factors, FIGURE 2 Network topology of the protein--protein interactions of our protein dataset as extracted from the STRING database steroids, all frequently used by IgAN patients including those in our study, may affect the complement system. However, it was reported that none of the above affected the serum concentration of either fibrinogen or complement C3 fragments. 38 Given the above, it seems that the simultaneous assessment of certain complement components, both in urine and serum (rather than in kidney biopsy), might be useful in the evaluation of IgAN. Moreover, 8 of 18 urinary proteins (47%) that were increased in our study are involved in complement activation and hemostasis, including: α-2-macroglobulin, ceruloplasmin, complement C3, complement C4A, haptoglobin, prothrombin, and antithrombin-III (ATIII). It is known that ATIII inhibits coagulation and inactivates the plasmin and complement system. All these facts link the complement activation pathways with platelet function and plasma coagulation factors. It appears that the stability of this system might be critical to the development and progression of IgAN.
In our opinion, urine proteomics might be an important tool, especially at the time of diagnosis and during exacerbations. In the first case, it may allow us to introduce an appropriate treatment, and in the second, it increases our chance of recognizing a relapse and prevent progression of IgAN. Currently, a practical approach in both situations involves estimation of daily proteinuria in combination with the serum creatinine concentration and the GFR change as a function of time. However, it is not surprising to see patients with daily proteinuria below 0.5 g but with high immune activity of the disease or advanced kidney fibrosis in renal histopathology. Therefore, a more sensitive methodology with a follow-up of IgAN patients is needed. This applies also to other glomerulopathies assessed by proteinuria. Additionally, we found 6 other proteins linked to proteolysis and 4 to cell-cell communication.
We demonstrated that the urine protein profile may be a useful tool to confirm IgAN in patients suspected of this glomerulonephritis. The limitation of our study was that we assessed proteins in the whole collected material. For this reason, we cannot indicate which protein might be a diagnostic marker of the disease activity and probably also of renal fibrosis due to IgAN. This resulted from the sensitivity of the methods, the fact that we looked for every protein with 2 peptides and more, as well as from limited financial resources. Further research is needed to address all those issues. Abbreviations: AFM -afamin, ALB -serum albumin, APOA1 -apolipoprotein A-I, AZGP1 -zinc-α-2-glycoprotein, A2M -alpha-2-macroglobulin, CA1 -carbonic anhydrase 1, CP -ceruloplasmin, C3 -complement C3, C4A -complement C4A, FN1 -fibronectin, F2 -prothrombin, GC -vitamin D-binding protein, HP -haptoglobin, IGFBP7 -insulin-like growth factor-binding protein 7, PSAP -proactivator polypeptide, SERPINA1 -α-1-antitrypsin, SERPINA3 -α-1-antichymotrypsin, SERPINC1 -antithrombin-III
